BR112015003913A2 - combinação de inibidor macrocíclico da protease do hcv, inibidor do hcv não nucleosídeo e ritonavir - Google Patents
combinação de inibidor macrocíclico da protease do hcv, inibidor do hcv não nucleosídeo e ritonavirInfo
- Publication number
- BR112015003913A2 BR112015003913A2 BR112015003913A BR112015003913A BR112015003913A2 BR 112015003913 A2 BR112015003913 A2 BR 112015003913A2 BR 112015003913 A BR112015003913 A BR 112015003913A BR 112015003913 A BR112015003913 A BR 112015003913A BR 112015003913 A2 BR112015003913 A2 BR 112015003913A2
- Authority
- BR
- Brazil
- Prior art keywords
- hcv
- inhibitor
- ritonavir
- combination
- nucleoside
- Prior art date
Links
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title abstract 3
- 239000002777 nucleoside Substances 0.000 title abstract 3
- 150000003833 nucleoside derivatives Chemical class 0.000 title abstract 3
- 229960000311 ritonavir Drugs 0.000 title abstract 3
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 title abstract 3
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 title 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 title 1
- 229940122604 HCV protease inhibitor Drugs 0.000 abstract 1
- 229940124772 HCV-NS5B polymerase inhibitor Drugs 0.000 abstract 1
- 108091005804 Peptidases Proteins 0.000 abstract 1
- 239000004365 Protease Substances 0.000 abstract 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/24—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12182551 | 2012-08-31 | ||
| EP12185890 | 2012-09-25 | ||
| PCT/IB2013/058138 WO2014033668A2 (en) | 2012-08-31 | 2013-08-30 | Combination of a macrocyclic protease inhibitor of hcv, a non-nucleoside hcv inhibitor and ritonavir |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112015003913A2 true BR112015003913A2 (pt) | 2017-07-04 |
Family
ID=49920362
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015003913A BR112015003913A2 (pt) | 2012-08-31 | 2013-08-30 | combinação de inibidor macrocíclico da protease do hcv, inibidor do hcv não nucleosídeo e ritonavir |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20150209366A1 (enExample) |
| EP (1) | EP2890378A2 (enExample) |
| JP (1) | JP2015526504A (enExample) |
| KR (1) | KR20150046083A (enExample) |
| CN (1) | CN104780921A (enExample) |
| AU (1) | AU2013311025A1 (enExample) |
| BR (1) | BR112015003913A2 (enExample) |
| CA (1) | CA2881052A1 (enExample) |
| IL (1) | IL237049A0 (enExample) |
| MX (1) | MX2015002684A (enExample) |
| RU (1) | RU2015111491A (enExample) |
| WO (1) | WO2014033668A2 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI454476B (zh) | 2008-07-08 | 2014-10-01 | Tibotec Pharm Ltd | 用作ｃ型肝炎病毒抑制劑之巨環吲哚衍生物 |
| CN106727516A (zh) * | 2017-01-10 | 2017-05-31 | 山东省立医院 | 一种治疗丙型肝炎的药物组合物 |
| US20210261111A1 (en) | 2018-06-27 | 2021-08-26 | Robert Bosch Gmbh | Method for operating a hybrid powertrain with an electric machine, an internal combustion engine and a variable transmission |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6037157A (en) | 1995-06-29 | 2000-03-14 | Abbott Laboratories | Method for improving pharmacokinetics |
| PE20070211A1 (es) * | 2005-07-29 | 2007-05-12 | Medivir Ab | Compuestos macrociclicos como inhibidores del virus de hepatitis c |
| TWI454476B (zh) | 2008-07-08 | 2014-10-01 | Tibotec Pharm Ltd | 用作ｃ型肝炎病毒抑制劑之巨環吲哚衍生物 |
| LT2401272T (lt) * | 2009-02-27 | 2017-03-27 | Janssen Pharmaceuticals, Inc. | Hcv makrociklinio slopiklio amorfinė druska |
| SG184524A1 (en) * | 2010-04-13 | 2012-11-29 | Janssen Pharmaceuticals Inc | Combination of a macrocyclic inhibitor of hcv, a non-nucleoside and a nucleoside |
-
2013
- 2013-08-30 JP JP2015529186A patent/JP2015526504A/ja active Pending
- 2013-08-30 RU RU2015111491A patent/RU2015111491A/ru not_active Application Discontinuation
- 2013-08-30 EP EP13818373.6A patent/EP2890378A2/en not_active Withdrawn
- 2013-08-30 MX MX2015002684A patent/MX2015002684A/es unknown
- 2013-08-30 KR KR1020157005596A patent/KR20150046083A/ko not_active Withdrawn
- 2013-08-30 AU AU2013311025A patent/AU2013311025A1/en not_active Abandoned
- 2013-08-30 BR BR112015003913A patent/BR112015003913A2/pt not_active IP Right Cessation
- 2013-08-30 CA CA2881052A patent/CA2881052A1/en not_active Abandoned
- 2013-08-30 WO PCT/IB2013/058138 patent/WO2014033668A2/en not_active Ceased
- 2013-08-30 US US14/422,005 patent/US20150209366A1/en not_active Abandoned
- 2013-08-30 CN CN201380045145.7A patent/CN104780921A/zh active Pending
-
2015
- 2015-02-02 IL IL237049A patent/IL237049A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2015111491A (ru) | 2016-10-20 |
| US20150209366A1 (en) | 2015-07-30 |
| CA2881052A1 (en) | 2014-03-06 |
| MX2015002684A (es) | 2015-05-12 |
| KR20150046083A (ko) | 2015-04-29 |
| JP2015526504A (ja) | 2015-09-10 |
| WO2014033668A3 (en) | 2014-05-01 |
| IL237049A0 (en) | 2015-03-31 |
| AU2013311025A1 (en) | 2015-02-26 |
| CN104780921A (zh) | 2015-07-15 |
| WO2014033668A2 (en) | 2014-03-06 |
| EP2890378A2 (en) | 2015-07-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20150199A (es) | Análogos de 2´-cloro nucleósido para infección por vhc | |
| ECSP099685A (es) | Compuestos de azufre como inhibidores de la serina proteasa ns3 del virus de la hepatitis c | |
| NZ702744A (en) | D-amino acid compounds for liver disease | |
| GT201400033A (es) | Pirimidinas anilladas sustituidas y uso de las mismas | |
| UY34570A (es) | Combinaciones de compuestos inhibidores de la proteína ns5a en el virus de hepatitis c | |
| ES2572329R1 (es) | Combinación de al menos dos agentes antivirales de acción directa y ribavirina pero no interferón, para uso en el tratamientodel vhc | |
| CL2011000145A1 (es) | Compuesto macrociclico derivado de quinoxalina y sus sales; inhibidor de la proteasa ns3 del virus de la hepatitis c(hcv); composicion farmaceutica que lo comprende; y uso en la prevencion o el tratamiento de una infeccion por hcv. | |
| CR20150058A (es) | Inhibidores de la proteasa ns3 del hcv | |
| WO2013074386A3 (en) | Hcv ns3 protease inhibitors | |
| GT201300208A (es) | Novedosos derivados de azabencimidazol cíclico útiles como agentes antidiabéticos | |
| CR20150337A (es) | Derivados de pirimidinona y su uso en el tratamiento, mejora o prevencion de una enfermedad viral | |
| ECSP12012349A (es) | Agentes inductores de apoptosis contra el cáncer y de enfermedades inmunes y autoinmunes | |
| ECSP12012348A (es) | Agentes inductores de apoptosis contra el cáncer y de enfermedades inmunes y autoinmunes | |
| MX2015011473A (es) | Compuesto de fosforamidato de nucleosido novedoso y su uso. | |
| WO2013106689A8 (en) | Hcv ns3 protease inhibitors | |
| WO2015095735A3 (en) | Vaccine compositions and uses thereof | |
| CO7131387A2 (es) | Composiciones y métodos de polipéptidos-complejo de quelato de oligonucleótido | |
| ECSP11011101A (es) | Compuestos cicloundecadepsipéptidos y el uso de dichos compuestos como un medicamento | |
| CR20130473A (es) | Genes que proporcionan resistencia al mildiú polvoroso en cucumis melo | |
| MX2013004906A (es) | Nuevos inhibidores especificos de la proteasa ns3 de hcv. | |
| AR093738A1 (es) | Formas solidas que comprenden inhibidores de ns5a de hcv, sus composiciones y sus usos | |
| CR20110527A (es) | Derivados de 1-alquil-cinolin-4(1h)-ona, su preparación y su aplicación en terapéutica | |
| ES2407409R1 (es) | Unidad de placa | |
| BR112015003913A2 (pt) | combinação de inibidor macrocíclico da protease do hcv, inibidor do hcv não nucleosídeo e ritonavir | |
| BR112012026016A2 (pt) | combinação de um inibidor macrocíclico de hcv, um não-nucleosídeo e um nucleosídeo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2477 DE 26-06-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |